Quantitative Proteomics Reveal That Metabolic Improvement Contributes to the Cardioprotective Effect of T(89) on Isoproterenol-Induced Cardiac Injury

BACKGROUND: T(89), a traditional Chinese medicine, has passed phase II, and is undergoing phase III clinical trials for treatment of ischemic cardiovascular disease by the US FDA. However, the role of T(89) on isoproterenol (ISO)-induced cardiac injury is unknown. The present study aimed to explore...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiao-Hong, Guo, Xiao, Pan, Chun-Shui, Li, Huan, Cui, Yuan-Chen, Yan, Li, Fan, Jing-Yu, Deng, Jing-Na, Hu, Bai-He, Chang, Xin, He, Shu-Ya, Yan, Lu-Lu, Sun, Kai, Wang, Chuan-She, Han, Jing-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273540/
https://www.ncbi.nlm.nih.gov/pubmed/34262469
http://dx.doi.org/10.3389/fphys.2021.653349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273540/
https://www.ncbi.nlm.nih.gov/pubmed/34262469
http://dx.doi.org/10.3389/fphys.2021.653349

Ejemplares similares